Method to Calculate the Protamine Dose Necessary for Reversal of Heparin as a Function of Activated Clotting Time in Patients Undergoing Cardiac Surgery

Journal of Extra-Corporeal Technology

Volumn 45, Issue 4, 2013, Pages 235-241

  Cuenca, Javier Suárez ^a   Diz, Pilar Gayoso ^b   Sampedro, Francisco Gude ^b   Marcos Gomez Zincke J ^a   Acuña, Helena Rey ^a   Manuela Fontanillo Fontanillo, M ^a  

^a UNIVERSITY OF VIGO   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

ACT; cardiopulmonary bypass; heparin; protamine

Indexed keywords

HEPARIN; PROTAMINE;

ACTIVATED CLOTTING TIME; ARTICLE; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; HEART SURGERY; HUMAN; MAJOR CLINICAL STUDY; NORMAL VALUE; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; STANDARDIZATION;

AGED; ALGORITHMS; CARDIOPULMONARY BYPASS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PROTAMINES; RETROSPECTIVE STUDIES; WHOLE BLOOD COAGULATION TIME;

EID: 84894065711     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bull BS, Huse WM, Brauer FS. Heparin therapy during extracorporeal circulation: II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg. 1975;69:685-9.
2. Hattersley PG. Activated coagulation time of whole blood. JAMA. 1966;196:436-40.
3. Jerez R, Martìn L, Lozano M. Anticoagulación durante la circulación extracorpó rea: control y reversió n. In: Gomar C, Mata MT, Pomar JL. (eds.) Fisiopatologìa y técnicas de circulació n extracorpórea. Barcelona, Spain: Ergon; 2012:307-23.
4. Weitkemper HH, Troitzsch D, Koerfer R. Realización prá ctica de la circulación extracorpó rea. Tschaut RJ. Circulació n extracorpórea en teorìa y práctica. Lengerich. Germany: Pabst Science Publishers; 2003:352-66.
5. Jobes DR. Safety issues in heparin and protamine administration for extracorporeal circulation. J Cardiothorac Vasc Anesth. 1998; 12(Suppl 1):17-20.
6. Lobato RL, Despotis GJ, Levy JH, et al. Anticoagulation management during cardiopulmonary bypass: A survey of 54 North American institutions. J Thorac Cardiovasc Surg. 2010;139:1665-6.
7. Bull MH, Huse WM, Bull BS. Evaluation of tests used to monitor heparin therapy during extracorporeal circulation. Anesthesiology. 1975;43:346-53.
8. Bull BS, Korpman RA, Huse WM, et al. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg. 1975;69:674-84.
9. Akl BF, Vargas GM, Neal J, et al. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1980;79:97-102.
10. Berger RL, Ramaswamy K, Ryan TJ. Reduced protamine dosage for heparin neutralization in open heart operations. Circulation. 1968;37:II154-157.
11. Guffin AV, Dunbar RW, Kaplan JA, et al. Successful use of a reduced dose of protamine after cardiopulmonary bypass. Anesth Analg. 1976;55:110-3.
12. Jobes DR, Schaffer GW, Aitken GL. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg. 1995;110:36-45.
13. Runge M, Møller CH, Steinbrü chel DA. Increased accuracy in heparin and protamine administration decreases bleeding: a pilot study. J Extra Corpor Technol. 2009;41:10-4 (abstract). 14. Mochizuki T, Olson PJ, Szlam F, et al. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg. 1998;87:781-5.
14. Mochizuki T, Olson PJ, Szlam F, et al. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg. 1998;87:781-5
15. Despotis GJ, Joist JH. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: An update. J Cardiothorac Vasc Anesth. 1999;13(Suppl 1):18-29.
16. Jaryno SA, Zucker ML, LaDuca FM. The Hemochron Response RxDx heparin and protamine dosing system. J Extra Corpor Technol. 2004;36:258-62 (abstract). 17. Milas BL, Jobes DR, Gorman RC. Management of bleeding and coagulopathy after heart surgery. Semin Thorac Cardiovasc Surg. 2000;12:326-36.
17. Milas BL, Jobes DR, Gorman RC. Management of bleeding and coagulopathy after heart surgery. Semin Thorac Cardiovasc Surg. 2000;12:326-36
18. Hensley FA, Martin DE, Gravlee GP. Anestesia Cardiaca. Madrid, Spain: Marbá n; 2004:511.
19. Charnaia MA, Morozov IuA, Gladysheva VG, et al. Comparison of two schemes of administering the Russian protamine sulfate after extracorporeal circulation in cardiosurgical patients. Anesteziol Reanimatol. 2006:31-3 (abstract).
20. Charnaia MA, Klypa TV, Morozov IuA, et al. Impact of protamine sulfate on hemostasis system after operations with artificial circulation. Khirurgiia (Mosk). 2007:17-20 (abstract).
21. Shore-Lesserson L, Reich DL, DePerio M. Heparin and protamine titration do not improve haemostasis in cardiac surgical patients. Can J Anaesth. 1998;45:10-8.
22. Hall RI. Protamine dosing-The quandary continues. Can J Anaesth. 1998;45:1-5.
23. Khan NU, Wayne CK, Barker J, et al. The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph. Eur J Anaesthesiol. 2010;27:624-7.
24. Instructions for use of the Activated Cotting Time Cartridges: Medtronic HR-ACT. Minneapolis, MN: Medtronic Inc., 2007.
25. Hill AG, Groom RC, Mario JA, et al. More precise heparin and protamine management during cardiopulmonary bypass. Proceedings of the American Academy of Cardiovascular Perfusion. 1990:12-16.
26. Despotis GJ, Joist JH, Hogue CW Jr, et al. More effective suppression of hemostasis system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost. 1996;67: 2-8.
27. Bowie JE, Kemna GD. Automated management of heparin anticoagulation in cardiovascular surgery. Proceedings of the American Academy of Cardiovascular Perfusion. 1985;6:1-5.